New medicines for lung scarring in scleroderma
Novel compounds for the treatment of systemic sclerosis-associated interstitial lung disease
This project is developing a new medicine to help people with lung scarring caused by scleroderma, a condition called SSc-ILD.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Eydis Bio, INC. NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11136500 on NIH RePORTER |
What this research studies
Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is a serious condition where lung tissue becomes scarred, and current treatments have limitations. Our team has found a key target called TAK1 that plays a role in the inflammation and scarring seen in SSc-ILD. We are developing a new oral medicine, HS-276, that specifically blocks TAK1. Early laboratory tests show that HS-276 can reduce scarring signals in human lung cells and lessen inflammation, and it has also shown promise in animal models of lung scarring. We aim to further develop this promising compound as a potential new treatment option.
Who could benefit from this research
Good fit: This early-stage research is not yet recruiting patients, but it is focused on developing therapies for individuals diagnosed with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Not a fit: Patients without SSc-ILD would not directly benefit from this specific treatment, as it is designed for the unique mechanisms of this lung condition.
Why it matters
Potential benefit: If successful, this new medicine could offer a more effective and safer treatment option for patients living with SSc-ILD, potentially slowing the progression of lung scarring and improving their quality of life.
How similar studies have performed: While TAK1 has been identified as a target in other fibrotic diseases, this specific compound (HS-276) and its application to SSc-ILD represent a novel approach building on promising preclinical findings.
Where this research is happening
Durham, United States
- Eydis Bio, INC. — Durham, United States (Active)
Researchers
- Principal investigator: Scarneo, Scott — Eydis Bio, INC.
- Study coordinator: Scarneo, Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.